XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Disaggregation of Revenue
Revenues recognized under these agreements were as follows (in thousands):
Three Months Ended
March 31,
20242023
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$— $11,440 
Research services variable consideration— 868 
Total$— $12,308 
Revenue related to Novartis agreement:
Recognition of upfront license fee$— $7,696 
Research services— 2,059 
Total$— $9,755 
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$— $130,630 
Cost-sharing payments for research services, net variable consideration— 1,672 
Total$— $132,302 
Revenue from other license agreements$481 $3,592 
Total revenue$481 $157,957